AEON and Blum Partner to Expand Crypto Payments and Bring Real-World Utility to $BLUM

AEON, the next-generation crypto payment framework, has announced a strategic partnership with Blum, a fast-rising decentralized multichain trading ecosystem, to integrate and support its newly listed token $BLUM across AEON Pay's real-world crypto payment infrastructure. Through this partnership, $BLUM holders can now spend their tokens across millions of online and offline merchants, including global brands […]

Copper Road announces the appointment of a new CEO

(TSX-V:CRD), TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Copper Road Resources Inc. (TSX-V: CRD) (“Copper Road” or the “Company”) announces the appointment of Mr. Brian Howlett as President and CEO, effectively immediately. Brian brings many years of experience in the junior exploration business previously serving in management or on the board of 9 junior mining

CryptoMiningFirm 2025 Trusted Free Bitcoin Cloud Mining Platform Launches New Mobile App

San Francisco, California, July 07, 2025 (GLOBE NEWSWIRE) — In the cryptocurrency space, few platforms have as high a revenue stream as CryptoMiningFirm – and CryptoMiningFirm is one of them. It provides a worry-free, secure, and environmentally friendly cloud mining experience to users around the world, allowing customers around the world to invest and earn

AIFU Announces $31.6 Million Non-Brokered Private Placement

(NASDAQ:AIFU), GUANGZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) — AIFU Inc. (Nasdaq: AIFU) (the “Company” or “AIFU”), a leading AI-driven independent financial services platform in China, today announced that it has entered into a definitive share purchase agreement (the “Agreement”) with certain investors, pursuant to which the investors have agreed to subscribe for, and the

Unisync announces the retirement of Douglas F. Good as CEO

(TSX:UNI),(OTC US:USYNF),(Other OTC:USYNF), TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Unisync Corp. (“Unisync”) (TSX: UNI) (OTC: USYNF) today announced that Douglas F. Good, the Company's Chief Executive Officer, will retire as CEO and a director effective July 15, 2025. Chairman Tim Gu will assume the role of Executive Chairman, providing continuity and oversight as the

Brixton Metals Announces Flow-Through Private Placement of $2.3 Million

(TSX-V:BBB),(OTC US:BBBXF),(Other OTC:BBBXF), Not for distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, July 07, 2025 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton“) is pleased to announce a non-brokered private placement offering (the “Offering”) of 17,692,308 flow-through common shares of

FuelCell Energy CEO Jason Few Applauds “One Big Beautiful Bill Act” as Catalyst for U.S. Clean Energy Leadership

(NasdaqGM:FCEL), DANBURY, Conn., July 07, 2025 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) President and CEO Jason Few has issued a statement praising the “One Big Beautiful Bill Act” (OBBBA) for its direct support of the fuel cell industry and its role in strengthening America's energy infrastructure, data center resilience, and clean manufacturing base.

Osisko Development Announces Positive Bulk Tonnage Ore Sorting Results for the Cariboo Gold Project

(TSX-V:ODV),(NYSE:ODV), HIGHLIGHTS X-ray transmission (XRT) ore sorter testwork of a ~80 tonne sample taken from the Cariboo underground achieved positive results consistent with 2025 FS parameters 42-55% waste rejection with 84-89% gold recovery achieved by sorting mid-size and oversize sample material including 10–30 mm and 30–70 mm size fractions, respectively Encouraging results from testing the

Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, double-blind, placebo-controlled Phase 2b study of sorafenib (SORA) with or without YIV-906 in advanced hepatocellular carcinoma (HCC) patients with chronic hepatitis B (HBV+). Results were highlighted in an American Society of Clinical

Scroll to Top